LONDON (Alliance News) - Verona Pharma PLC said Wednesday it has completed the enrollment for its Phase 2 clinical trial evaluating the effect of nebulised RPL554 as an add-on to dual therapy in respiratory disease.
The clinical-stage biopharmaceutical company said it expects to report top line data from the trial in January.
A total of 79 patients with moderate to severe chronic obstructive pulmonary disease have been enrolled for the trial in the UK and US.
The randomised, double-blind trial is designed to investigate the efficacy and safety of nebulised RPL554 as an add-on to an inhaled LAMA/LABA treatment, compared to placebo.
"Those patients already receiving inhaled corticosteroid anti-inflammatory therapy will continue a stable dose of ICS throughout the study, thus providing additional data on 'triple therapy' use," the company explained.
The primary endpoint of the trial is to show improvement in lung function with RPL554 versus placebo, measured by peak forced expired volume in one second, a standard measure of exhaled breath volume to evaluate respiratory function.
Verona Pharma shares were untraded at 117.50 pence each on Wednesday.